315 related articles for article (PubMed ID: 21616107)
1. Lactose characteristics and the generation of the aerosol.
Pilcer G; Wauthoz N; Amighi K
Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
[TBL] [Abstract][Full Text] [Related]
2. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
Donovan MJ; Smyth HD
Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
[TBL] [Abstract][Full Text] [Related]
3. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
Zhou QT; Morton DA
Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
[TBL] [Abstract][Full Text] [Related]
4. Physico-chemical aspects of lactose for inhalation.
Kou X; Chan LW; Steckel H; Heng PW
Adv Drug Deliv Rev; 2012 Mar; 64(3):220-32. PubMed ID: 22123598
[TBL] [Abstract][Full Text] [Related]
5. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
6. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
7. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
8. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
de Boer AH; Chan HK; Price R
Adv Drug Deliv Rev; 2012 Mar; 64(3):257-74. PubMed ID: 21565232
[TBL] [Abstract][Full Text] [Related]
9. Dry powder inhaler device influence on carrier particle performance.
Donovan MJ; Kim SH; Raman V; Smyth HD
J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
[TBL] [Abstract][Full Text] [Related]
10. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
Shalash AO; Molokhia AM; Elsayed MM
Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
[TBL] [Abstract][Full Text] [Related]
11. Dry powders for oral inhalation free of lactose carrier particles.
Healy AM; Amaro MI; Paluch KJ; Tajber L
Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
[TBL] [Abstract][Full Text] [Related]
12. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
13. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
[TBL] [Abstract][Full Text] [Related]
14. Lactose as a carrier for inhalation products: breathing new life into an old carrier. Preface.
Marriott C; Frijlink HW
Adv Drug Deliv Rev; 2012 Mar; 64(3):217-9. PubMed ID: 22146699
[No Abstract] [Full Text] [Related]
15. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
16. Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy. 1: Budesonide and lactose.
Marek SR; Donovan MJ; Smyth HD
Eur J Pharm Biopharm; 2011 May; 78(1):97-106. PubMed ID: 21182942
[TBL] [Abstract][Full Text] [Related]
17. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
18. Alternative carriers in dry powder inhaler formulations.
Rahimpour Y; Kouhsoltani M; Hamishehkar H
Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
[TBL] [Abstract][Full Text] [Related]
19. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
20. Effect of carrier particle shape on dry powder inhaler performance.
Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
